{"id":555842,"date":"2021-08-03T14:48:02","date_gmt":"2021-08-03T14:48:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=555842"},"modified":"2021-08-03T14:48:02","modified_gmt":"2021-08-03T14:48:02","slug":"chemotherapyinduced-peripheral-neuropathy-market-expected-to-grow-due-to-increased-spending-on-rd-as-well-as-the-introduction-of-novel-therapies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chemotherapyinduced-peripheral-neuropathy-market-expected-to-grow-due-to-increased-spending-on-rd-as-well-as-the-introduction-of-novel-therapies_555842.html","title":{"rendered":"Chemotherapy-Induced Peripheral Neuropathy Market Expected to grow due to increased spending on R&#038;D as well as the introduction of novel therapies"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1627974387.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Chemotherapy-Induced Peripheral Neuropathy Market Expected to grow due to increased spending on R&amp;D as well as the introduction of novel therapies\" src=\"https:\/\/www.abnewswire.com\/uploads\/1627974387.png\" alt=\"Chemotherapy-Induced Peripheral Neuropathy Market Expected to grow due to increased spending on R&amp;D as well as the introduction of novel therapies\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Chemotherapy-Induced Peripheral Neuropathy Market <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The launch of therapies such as SP-04, Halneuron, and others are anticipated to provide a major push to the growth of the Chemotherapy-Induced Peripheral Neuropathy market size in the forecast period 2020-30 in the 7MM.\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/551c9430d53aca728b50e47dcad31390.jpg\" alt=\"\" \/><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight&#8217;s <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cipn-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Chemotherapy-Induced Peripheral Neuropathy market report<\/a><\/strong><span> covers historical and predicted epidemiology, as well as Chemotherapy-Induced Peripheral Neuropathy market trends in the 7MM (the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan). The report also covers current Chemotherapy-Induced Peripheral Neuropathy treatment methods\/algorithms, Chemotherapy-Induced Peripheral Neuropathy market drivers, Chemotherapy-Induced Peripheral Neuropathy, and unmet medical needs.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the Important Findings from the Chemotherapy-Induced Peripheral Neuropathy Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>As per DelveInsight&rsquo;s Chemotherapy-Induced Peripheral Neuropathy epidemiology insights, the incident population was estimated to be more than <\/span><strong>590,000 <\/strong><span>out of which the moderate cases were higher than mild and severe CIPN in the United States in 2017.&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Japan accounted for approximately <\/span><strong>18.11%<\/strong><span> of the total CIPN incident cases in the 7MM in 2017.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Among the EU5 countries, <\/span><span><strong>Germany<\/strong> <\/span><span>had the highest CIPN incident cases while <\/span><span><strong>Spain<\/strong> <\/span><span>had the lowest CIPN incident population in 2017.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>The major key players including <\/span><strong>Solasia, WEX Pharmaceuticals, ESTEVE (E-52862), <\/strong><span>and others&nbsp;<\/span><span>hold the potential to create a significant positive shift in CIPN market size.&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>E-52862 (MR309)<\/strong><span> developed by <\/span><span><strong>ESTEVE<\/strong> <\/span><span>is a selective 1R antagonist that has recently completed Phase II clinical trials for neuropathic pain and could be a first-in-class analgesic.&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>SP-04<\/strong><span>, developed by <\/span><strong>Pledpharma<\/strong><span> and acquired by <\/span><strong>Solasia<\/strong><span>, is a first-in-class drug candidate designed to protect patients with adjuvant or metastatic colorectal cancer from the nerve damage that can occur during chemotherapy treatment.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Want to learn more? Request sample @ <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cipn-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Chemotherapy-Induced Peripheral Neuropathy Treatment Guidelines<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Chemotherapy-Induced Peripheral Neuropathy market report<\/strong><span> covers current treatment practices, emerging drugs, Chemotherapy-Induced Peripheral Neuropathy market share of individual therapies, and current and forecasted Chemotherapy-Induced Peripheral Neuropathy market size from 2017 to 2030, segmented by seven major markets.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chemotherapy-Induced Peripheral Neuropathy: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a common, dose-dependent side effect of anticancer drugs such as platinums, taxanes, epothilones, vinca alkaloids, and newer agents like bortezomib. It not only causes dose reductions or treatment discontinuation, but it also lowers the quality of life of cancer survivors. CIPN occurs in 20% of patients receiving standard chemotherapy doses and in nearly 100% of patients receiving high doses.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chemotherapy-Induced Peripheral Neuropathy Epidemiology Segmentation<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>The Chemotherapy-Induced Peripheral Neuropathy report proffers epidemiological analysis for the study period 2017-30 in the 7MM segmented into:<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Chemotherapy-Induced Peripheral Neuropathy Total Incident Cases&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Chemotherapy-Induced Peripheral Neuropathy Severity-Specific Incident Population<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Chemotherapy-Induced Peripheral Neuropathy Incident Population by Chemotherapeutic Agents&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Chemotherapy-Induced Peripheral Neuropathy Incident Population by Cancer Type<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chemotherapy-Induced Peripheral Neuropathy Treatment Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Due to the lack of approved targeted therapies, the current CIPN therapeutic landscape in the 7MM is dominated by off-label therapies. Major Off-label therapies used to treat CIPN symptoms include <\/span><span>alpha-2-delta antagonists (anticonvulsants), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), opioids, and topical analgesics.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><strong>Chemotherapy-Induced Peripheral Neuropathy Market<\/strong>&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>The launch of therapies such as <\/span><strong>SP-04, Halneuron, E-52862, <\/strong><span>and others by key pharmaceutical companies such as <\/span><strong>Solasia, WEX Pharmaceuticals, ESTEVE, <\/strong><span>and several others<\/span><span> is anticipated to provide a major push to the growth of the CIPN market size in the forecast period 2020-30 in the 7MM.&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Find out which player or emerging drug is going to get the maximum share @ <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cipn-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Chemotherapy-Induced Peripheral Neuropathy Market Size<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><strong>Chemotherapy-Induced Peripheral Neuropathy Pipeline Therapies and Key Players<\/strong>&nbsp;<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>SP-04: <\/span><span>Solasia<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Halneuron: <\/span><span>WEX Pharmaceuticals<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>E-52862: <\/span><span>ESTEVE<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chemotherapy-Induced Peripheral Neuropathy Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Increasing CIPN emerging therapies<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Increasing awareness<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chemotherapy-Induced Peripheral Neuropathy Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>No standard assessment<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Current therapy limitations<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Herbal remedies<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Clinical understanding<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope for the Report<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Coverage: <\/strong><span>7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Study Period: <\/strong><span>2017-30<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>CIPN Key Companies: <\/strong><span>Solasia, WEX Pharmaceuticals, ESTEVE,<\/span><span> among others.<\/span><span>&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>CIPN Key Pipeline Therapies: <\/strong><span>SP-04, Halneuron, E-52862,<\/span><span>and others.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>CIPN Segmentation: <\/strong><span>By Geography, By CIPN therapies<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><strong>Analysis:<\/strong> <\/span><span>Comparative and conjoint analysis of <\/span><span>CIPN <\/span><span>&nbsp;emerging therapies<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Tools Used: <\/strong><span>SWOT Analysis<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Case Studies<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>KOL&rsquo;s Views<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analyst&rsquo;s Views<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><span>&nbsp;<\/span><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"64\" \/>\n<col width=\"560\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><span>1.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Key Insights<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>2.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Executive Summary of Chemotherapy-Induced Peripheral Neuropathy<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>3.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Chemotherapy-Induced Peripheral Neuropathy: Market Overview at a Glance<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>4.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Chemotherapy-Induced Peripheral Neuropathy: Disease Background and Overview<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>5.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>CIPN Case Reports<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>6.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>CIPN Patient Journey<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>7.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>CIPN Epidemiology and Patient Population<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>8.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>CIPN Assumptions and Rationale: 7MM<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>9.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Country Wise-Epidemiology of CIPN<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>10.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>CIPN Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>11.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>CIPN Unmet Needs<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>12.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>CIPN Emerging Therapies<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>13.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Chemotherapy-Induced Peripheral Neuropathy: 7MM Market Analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>14.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>CIPN Key Market Forecast Assumptions<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>15.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>CIPN United States: Market Outlook<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>16.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>CIPN EU-5 countries: Market Outlook<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>17.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>CIPN Japan Market Outlook<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>18.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>CIPN Market Drivers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>19.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>CIPN Market Barriers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>20.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>SWOT Analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>21.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Appendix<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>22.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>DelveInsight Capabilities<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>23.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Disclaimer<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>24.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>About DelveInsight<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>For rich insights into Healthcare and Pharmaceutical News, visit <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Pharma, Healthcare, and Biotech Blog Posts<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chemotherapy-induced-neutropenia-cin-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Chemotherapy Induced Neutropenia Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Get comprehensive historical and forecast analysis of <\/span><span>Chemotherapy Induced Neutropenia<\/span><span> Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as <\/span><strong>Amgen, G1 Therapeutics, Evive Biotech, Myelo Therapeutics, Cellerant Therapeutics, Aileron Therapeutics, Spectrum Pharmaceuticals,&nbsp;<\/strong><span>among others.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=chemotherapyinduced-peripheral-neuropathy-market-expected-to-grow-due-to-increased-spending-on-rd-as-well-as-the-introduction-of-novel-therapies\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=chemotherapyinduced-peripheral-neuropathy-market-expected-to-grow-due-to-increased-spending-on-rd-as-well-as-the-introduction-of-novel-therapies\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chemotherapy-Induced Peripheral Neuropathy Market The launch of therapies such as SP-04, Halneuron, and others are anticipated to provide a major push to the growth of the Chemotherapy-Induced Peripheral Neuropathy market size in the forecast period 2020-30 in the 7MM. DelveInsight&#8217;s &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/chemotherapyinduced-peripheral-neuropathy-market-expected-to-grow-due-to-increased-spending-on-rd-as-well-as-the-introduction-of-novel-therapies_555842.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,403,404],"tags":[],"class_list":["post-555842","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/555842","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=555842"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/555842\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=555842"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=555842"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=555842"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}